Opinion and Comment バイオ企業と製薬企業の商品開発のベンチマーキング 2014年7月1日 Nature Biotechnology 32, 7 doi: 10.1038/nbt.2947 The biotech sector's record in originating high-priority medicines exceeds that of the pharmaceutical industry, its costs are lower and its products have comparable revenues. Full text PDF 目次へ戻る